Business, energy, technology, markets and global industry news from Business News Today

melanocortin system

PharmaDeviceNews melanocortin system
Representative image: Kalohexis’ 710GO obesity drug research highlights how dual MC3R/MC4R activation could reshape oral weight loss therapy beyond GLP-1 medicines.
Pharma & Biotech

Kalohexis 710GO data highlight a differentiated obesity mechanism as Phase 1 moves ahead

Read how Kalohexis’ 710GO could challenge GLP-1 obesity drugs with dual MC3R/MC4R activation, lean-mass sparing and durability.

Read More
Representative image of obesity treatment research. Kalohexis’ 710GO data highlights growing interest in dual MC3R and MC4R activation as the next frontier in weight loss drug development.
Pharma & Biotech

Kalohexis 710GO data puts melanocortin obesity drugs back in the metabolic spotlight

GLP-1 drugs dominate obesity care, but Kalohexis is testing a different pathway. 710GO could shift the next weight loss race.

Read More